1672 Share Price Performance
HK$10.88
9.42 (645.21%)
Price HK$10.88
Share PriceHK$10.88
Ascletis Pharma Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
1672 Community Narratives
There are no narratives available yet.
Recent 1672 News & Updates
Ascletis Pharma Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.26
- Gross Margin
- 36.21%
- Net Profit Margin
- -10,937.78%
- Debt/Equity Ratio
- 0%
Ascletis Pharma Inc. Competitors
Snowflake Analysis
About 1672
- Founded
- 2013
- Employees
- 208
- CEO
- WebsiteView website
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Chinese Market Performance
- 7 Days: 0.5%
- 3 Months: 17.0%
- 1 Year: 24.1%
- Year to Date: 26.2%
Over the last 7 days, the market has remained flat, with no particular sector making any big moves this week. As for the longer term, the market has risen 24% in the past 12 months. Earnings are forecast to grow by 27% annually. Market details ›